Crinetics Pharmaceuticals ( NASDAQ: CRNX ) has been at the forefront of advancing novel therapeutics aimed at addressing unmet medical needs. With a primary focus on rare endocrine diseases and endocrine-related tumors, the company's innovative approach has sparked interest among many investors and stakeholders